Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (25.0%)
N/A3 (75.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers

NCT02331147
completednot_applicable

DHACM vs Other Commercially Available Treatments

NCT01921491
completedphase_4

GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers

NCT02675855
unknownnot_applicable

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

NCT02399826

Clinical Trials (4)

Showing 4 of 4 trials
NCT02331147Not Applicable

Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers

Completed
NCT01921491Not Applicable

DHACM vs Other Commercially Available Treatments

Completed
NCT02675855Phase 4

GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers

Completed
NCT02399826Not Applicable

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

Unknown

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4